MA43283B1 - Composition pour le traitement du cancer - Google Patents

Composition pour le traitement du cancer

Info

Publication number
MA43283B1
MA43283B1 MA43283A MA43283A MA43283B1 MA 43283 B1 MA43283 B1 MA 43283B1 MA 43283 A MA43283 A MA 43283A MA 43283 A MA43283 A MA 43283A MA 43283 B1 MA43283 B1 MA 43283B1
Authority
MA
Morocco
Prior art keywords
peptide
cancer
expressing
administering
induction
Prior art date
Application number
MA43283A
Other languages
English (en)
Other versions
MA43283A (fr
Inventor
David A Scheinberg
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA43283A publication Critical patent/MA43283A/fr
Publication of MA43283B1 publication Critical patent/MA43283B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Abstract

L'invention concerne des procédés de traitement, de réduction de l'incidence des réponses immunitaires et de leur induction vis-à-vis d'un cancer exprimant wt1, par l'administration d'une combinaison d'au moins un peptide wt1, ou de lymphocytes t cytotoxiques (ctl) contre un cancer exprimant wt1, et d'au moins un inhibiteur de point de contrôle. Ledit ou les lesdits peptides wt1 peuvent être administrés au sujet par administration d'un ou de plusieurs agents au sujet entraînant l'apport d'un ou plusieurs peptides wt1 et l'induction d'une réponse immunitaire contre le cancer exprimant wt1. Des exemples de ces agents d'administration wt1 comprennent : (i) un peptide wt1 isolé, (ii) un acide nucléique codant pour le ou les peptides wt1, et (iii) une cellule immunitaire comprenant ou présentant le ou les peptides wt1 ou un acide nucléique codant pour le ou les peptides wt1.
MA43283A 2015-11-20 2016-11-18 Composition pour le traitement du cancer MA43283B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258134P 2015-11-20 2015-11-20
PCT/US2016/062865 WO2017087857A1 (fr) 2015-11-20 2016-11-18 Procédés et compositions pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA43283A MA43283A (fr) 2018-09-26
MA43283B1 true MA43283B1 (fr) 2022-08-31

Family

ID=58717878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43283A MA43283B1 (fr) 2015-11-20 2016-11-18 Composition pour le traitement du cancer

Country Status (19)

Country Link
US (1) US11033613B2 (fr)
EP (2) EP4130026A1 (fr)
JP (3) JP6991969B2 (fr)
KR (1) KR20180094922A (fr)
CN (4) CN116327903A (fr)
AU (2) AU2016356708B2 (fr)
CA (1) CA3005896A1 (fr)
DK (1) DK3377516T3 (fr)
ES (1) ES2926386T3 (fr)
HR (1) HRP20220994T1 (fr)
HU (1) HUE059694T2 (fr)
LT (1) LT3377516T (fr)
MA (1) MA43283B1 (fr)
MD (1) MD3377516T2 (fr)
PL (1) PL3377516T3 (fr)
PT (1) PT3377516T (fr)
RS (1) RS63561B1 (fr)
SI (1) SI3377516T1 (fr)
WO (1) WO2017087857A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polythérapie anticancéreuse à base de smc
CN116327903A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
CN116970060A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118A4 (fr) 2017-03-15 2021-04-07 Cue Biopharma, Inc. Procédés pour moduler une réponse immunitaire
WO2019006401A2 (fr) * 2017-06-30 2019-01-03 Advaxis, Inc. Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms hétéroclitique et procédés d'utilisation correspondants
EP3678701A4 (fr) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
KR20200070405A (ko) * 2017-11-08 2020-06-17 어드박시스, 인크. 암 관련 단백질로부터의 면역원성 불규칙변화성 펩타이드 및 그것의 사용 방법
EP3737689A4 (fr) 2018-01-09 2021-12-01 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
US20210047363A1 (en) * 2018-03-06 2021-02-18 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
KR20210073540A (ko) * 2018-10-05 2021-06-18 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 양성 종양의 예방 또는 치료약
TW202039542A (zh) * 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
KR20220010712A (ko) * 2019-04-10 2022-01-26 에스엘에스지 리미티드 엘엘씨 Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법
EP4085130A4 (fr) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus
CN115666542A (zh) * 2020-04-07 2023-01-31 梅塔诺伊治疗公司 用于治疗上皮性卵巢癌的乙醇胺调配物
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1995004064A1 (fr) 1993-07-29 1995-02-09 The Regents Of The University Of California Leurres polynucleotidiques inhibant l'expression du complexe d'histocompatibilite majeure ii, et applications
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
WO2001025273A2 (fr) 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes se rapportant a une immunotherapie specifique a wt1
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003106682A1 (fr) 2002-06-12 2003-12-24 中外製薬株式会社 Peptide antigene du cancer a restriction hla-a24
EP2343083B1 (fr) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Procédé de diagnostic du cancer comprenant la mesure de la fréquence de cellules précurseurs des LTC de WTI
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
US20060127409A1 (en) 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
EP1708732B2 (fr) 2003-12-01 2016-05-18 Sloan-Kettering Institute For Cancer Research Analogues peptidiques synthetiques de liaison a l'antigene histocompatibilite et leurs utilisations
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
DE102006014261A1 (de) 2006-03-28 2007-10-04 Dr.Ing.H.C. F. Porsche Ag Luftleitvorrichtung für ein Fahrzeug
CA2645766A1 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides wt1 immunogenes et leurs methodes d'utilisation
CA2881594C (fr) 2007-12-05 2016-04-12 International Institute Of Cancer Immunology, Inc. Composition de vaccin contre le cancer
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
EP3520810A3 (fr) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Peptides wt1 immunogènes et ses utilisations
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961702B (zh) * 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
EP3607974A1 (fr) * 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Vaccins contre le cancer et procédés de traitement les utilisant
MX2016005283A (es) 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
WO2015103602A1 (fr) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunothérapie
US9364523B2 (en) 2014-03-17 2016-06-14 Tapimmune Inc. Chimeric nucleic acid molecule with non-AUG translation initiation sequences
WO2016186177A1 (fr) 2015-05-20 2016-11-24 大日本住友製薬株式会社 Combinaison de peptide d'antigène wt1 et d'immunomodulateur
CN116327903A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物

Also Published As

Publication number Publication date
MD3377516T2 (ro) 2022-10-31
CA3005896A1 (fr) 2017-05-26
US20180339030A1 (en) 2018-11-29
JP2024041809A (ja) 2024-03-27
CN116327902A (zh) 2023-06-27
WO2017087857A1 (fr) 2017-05-26
CN108431022A (zh) 2018-08-21
DK3377516T3 (da) 2022-09-19
LT3377516T (lt) 2022-09-26
EP3377516B1 (fr) 2022-06-15
SI3377516T1 (sl) 2023-01-31
RS63561B1 (sr) 2022-10-31
ES2926386T3 (es) 2022-10-25
JP2022033926A (ja) 2022-03-02
HRP20220994T1 (hr) 2022-11-11
CN115920017A (zh) 2023-04-07
HUE059694T2 (hu) 2022-12-28
PT3377516T (pt) 2022-09-23
EP3377516A4 (fr) 2019-06-26
EP3377516A1 (fr) 2018-09-26
JP2018538265A (ja) 2018-12-27
PL3377516T3 (pl) 2022-10-10
MA43283A (fr) 2018-09-26
EP4130026A1 (fr) 2023-02-08
AU2016356708B2 (en) 2022-02-03
CN116327903A (zh) 2023-06-27
AU2022202973A1 (en) 2022-05-26
KR20180094922A (ko) 2018-08-24
US11033613B2 (en) 2021-06-15
JP6991969B2 (ja) 2022-03-03
CN108431022B (zh) 2022-08-09
AU2016356708A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MA43283B1 (fr) Composition pour le traitement du cancer
MA42020A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA43075A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA42021A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
WO2016106404A3 (fr) Méthodes et compositions destinées à traiter les tumeurs malignes associées à une mutation de kras
MA46022B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA40794A1 (fr) Nouveaux peptides et combinaisons de peptides et d'échafaudages destinés à être utilisés en immunothérapie contre le carcinome hépatocellulaire (chc) et d'autres cancers
MA43719B1 (fr) Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
MA43459A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
IN2014KN01713A (fr)
IN2014KN01714A (fr)
IN2014KN01716A (fr)
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
MA43618A1 (fr) Nouveaux peptides, association de peptides en tant que cibles et destinés à être utilisés en immunothérapie contre le cancer de la vésicule biliaire et le cholangiocarcinome et autres cancers
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
Huang et al. LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes in human macrophages and LACC1 risk variants modulate these outcomes
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
Khalili et al. Long acting propranolol and HSP-70 rich tumor lysate reduce tumor growth and enhance immune response against fibrosarcoma in Balb/c mice
AU2021303517A8 (en) System
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ